Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -202620252024202320222021202020192018201720162015 1 September 2022 BIOCARTIS ANNOUNCES H1 2022 RESULTS Regulated information 1 September 2022 Biocartis Initiates Commercialization in Europe of SkylineDx’s Innovative Merlin™ Assay (CE-IVD) for Melanoma Patients Non-regulated information 1 September 2022 Biocartis Announces Entry into Comprehensive Recapitalization Arrangements to Strengthen Cash Position and Support Growth Inside information Regulated information 25 August 2022 Biocartis Announces 2022 Half-Year Results on 1 September 2022 Regulated information 24 August 2022 Biocartis Obtains ISO 27001 Certification for Information Security Management Non-regulated information 22 June 2022 Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso® Non-regulated information 20 June 2022 Biocartis Announces Launch of its Rapid CE-marked IVD Idylla™ GeneFusion Panel for Fast Treatment Decisions in Lung Cancer Non-regulated information 15 June 2022 Biocartis Reaches Key Commercial Milestones: One-Millionth Idylla™ Cartridge Sold and 2,000th Idylla™ Instrument Placed Non-regulated information 13 May 2022 Results of the Annual Shareholders’ Meeting held on 13 May 2022 Regulated information 4 May 2022 New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ GeneFusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods Non-regulated information Pagination First page « First Previous page ‹‹ … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page ›› Last page Last »